Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 10/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521717 | 0.85 | GRM2 (0.60) | GRM2 | |
| SCHEMBL756737 | 0.85 | GRM2 (0.50) | GRM2NPSR1KDM4EHPGDADORA1 | |
| SCHEMBL4526237 | 0.81 | GRM2 (0.54) | GRM2NPSR1KDM4EHPGDRXFP1 | |
| SCHEMBL4523157 | 0.81 | GRM2 (0.43) | GRM2NPSR1KDM4EHPGDRXFP1 | |
| SCHEMBL4526619 | 0.81 | GRM2 (0.43) | GRM2NPSR1KDM4EHPGDRXFP1 | |
| SCHEMBL19610600 | 0.80 | GRM2 (0.48) | GRM2NPSR1KDM4EHPGDRXFP1 | |
| SCHEMBL4521921 | 0.80 | ADORA1 (0.41) | GRM2KDM4EHPGDADORA2BADORA1 | |
| SCHEMBL19610610 | 0.79 | RIPK1 (0.47) | GRM2NPSR1KDM4EKDRMAPT | |
| SCHEMBL7803931 | 0.75 | GRM2 (0.44) | GRM2 | |
| SCHEMBL4516374 | 0.74 | TOP2A (0.48) | NPSR1KDM4EHPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | US | disclosed |
| EP-1934205-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | Merck Frosst Canada Ltd. (CA) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054483-A1 | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, LTB4R2 | GRM2 4204/4885NPSR1 450/4885KDM4E 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.